Search clinical trials for: Cabotegravir OLI

Total 2877 results

ViiV Healthcare

Active, not recruiting

A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States (PILLAR)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Gilead Sciences; ViiV Healthcare

Active, not recruiting

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

HIV Infections

Brazil, United States, South Africa, Peru, Thailand, Argentina, Vietnam
ViiV Healthcare

Completed

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare

Completed

A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation

HIV Infections

United States
ViiV Healthcare

Recruiting

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants

HIV Infections

United States
ViiV Healthcare

Available

GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV

Infection, Human Immunodeficiency Virus
ViiV Healthcare

Recruiting

A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

HIV Infections

United States
Centre for the AIDS Programme of Research in South...
ViiV Healthcare

Withdrawn

Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa (CAPRISA014)

Human Immunodeficiency Virus

South Africa
Kelley-Ross & Associates, Inc.

Not yet recruiting

Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting. (IDCaPP)

HIV Infections

United States
ViiV Healthcare
Glaxosmithkline/Quintiles

Completed

A Study to Evaluate the Effect of High Fat Meal on Cabotegravir

Infection, Human Immunodeficiency Virus

United States
University Paris 7 - Denis Diderot
Hopital Foch

Not yet recruiting

Patient-Reported Outcomes in Real-life of Cabotegravir and Rilpivirine (PANTER)

Quality of Life
ViiV Healthcare
Janssen Research and Development

Active, not recruiting

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults (ATLAS-2M)

HIV Infections

United States, Germany, Spain, France, Canada, Korea, Republic of, Italy, South Africa, Australia, Russian Federation, Mexico, Sweden, Argentina
Oregon Health and Science University
ViiV Healthcare

Recruiting

Oregon PrEP at Home Study (OR-PrEP@Home)

HIV/AIDS

United States
ViiV Healthcare

Recruiting

A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories (EBONI)

HIV Infections

United States
Evandro Chagas National Institute of Infectious...
Beatriz Grinsztejn; Thiago Torres; Valdilea Gonçalves; Brenda Hoagland

Not yet recruiting

The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir (ImPrepCab)

HIV Infections

Brazil
ViiV Healthcare

Completed

Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers

HIV Infections | Infection, Human Immunodeficiency Virus

United States
Beth Israel Deaconess Medical Center
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana (Tshireletso)

Breast Feeding | Pre-Exposure Prophylaxis (PrEP)

United States, Botswana
Midway Specialty Care Center

Recruiting

Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP

Hiv

United States
MRC/UVRI and LSHTM Uganda Research Unit
London School of Hygiene and Tropical Medicine; Assistance Publique - Hôpitaux... and other collaborators

Not yet recruiting

Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa (MOBILEMEN)

HIV
ViiV Healthcare
Janssen, LP

Completed

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (SOLAR)

HIV Infections

United States, Netherlands, Germany, Canada, Australia, Belgium, France, Spain, Ireland, Italy, United Kingdom, Austria, Japan, Switzerland
University College, London
London School of Hygiene and Tropical Medicine; MRC/UVRI and LSHTM Uganda Research... and other collaborators

Active, not recruiting

Long-Acting Treatment in Adolescents (LATA) (LATA)

HIV Infections | Hiv | HIV-1-infection | Paediatric Human Immunodeficiency Virus Infection

Uganda, Zimbabwe, Kenya, South Africa
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants

HIV Infections

United States
ViiV Healthcare

Completed

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

HIV Infections

United States, New Zealand
University of California, San Francisco
National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute... and other collaborators

Active, not recruiting

SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension

HIV

Kenya, Uganda
National Institute of Allergy and Infectious Diseases...
ViiV Healthcare

Active, not recruiting

More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (MOCHA)

HIV Infections

Thailand, United States, Botswana, Uganda, South Africa
Whitman-Walker Institute
ViiV Healthcare

Enrolling by invitation

Clinical Effectiveness-Implementation Hybrid Type 2 Study on Home-Delivered Cabenuva for People Living With HIV Who Are Not Retained in Care (CREATE)

HIV

United States
University of Zurich
Swiss HIV Cohort Study

Recruiting

Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures

HIV Infections

Switzerland
ViiV Healthcare
Janssen Research and Development

Completed

A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants

Human Immunodeficiency Virus Type 1 (HIV-1)

Germany, Spain, United States, Italy, Canada, Argentina, Sweden
Karolinska Institutet

Withdrawn

Intervention Study to Prevent Obesity in Sedentary 8 Year Old Swedish Children (STOPP-8)

Overweight | Sedentary Lifestyle | Cardiovascular Risk Factors | Metabolic Risk Factors

Sweden
ANRS, Emerging Infectious Diseases

Not yet recruiting

Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France. (CABOPrEP)

Prevention

France
National Institute of Allergy and Infectious Diseases...
ViiV Healthcare

Completed

Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

HIV Infections

United States, Puerto Rico
Castagna Antonella

Recruiting

Cohort Study of HIV-positive People, Treated With Long Acting Antiretroviral Therapy (SCohoLART)

HIV Infections

Italy
George Washington University
Naval Medical Research Center; Clinica de la Costa; Global Disease Research

Recruiting

Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE) (ZAP-DENGUE)

Dengue Fever

Colombia
Yale University
ViiV Healthcare

Not yet recruiting

Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs

Hiv

United States
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Active, not recruiting

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada, Australia, Korea, Republic of, Italy, South Africa, Russian Federation, Argentina, Mexico, Sweden
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Active, not recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

HIV Infections

United States, Germany, Netherlands, Spain, France, Canada, United Kingdom, Italy, South Africa, Russian Federation, Japan
Boston Medical Center
ViiV Healthcare

Completed

Improving Treatment and Retention Adherence in Nontraditional Settings (I-TRAINS)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females - A Sub-study of HPTN 084

HIV Infections

Zimbabwe, South Africa, Uganda
ViiV Healthcare
GlaxoSmithKline; PPD

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (VOLITION)

HIV Infections

United States, France, Germany, Canada, Spain, Italy, Argentina, Chile, Puerto Rico
ViiV Healthcare

Completed

Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.) (GLACIER)

HIV Infections

United States
University of Witwatersrand, South Africa
Bill and Melinda Gates Foundation; ViiV Healthcare

Active, not recruiting

Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa (AXIS)

HIV Infections

South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males - A Sub-study of HPTN 083

HIV Infections

United States
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Active, not recruiting

Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine (HOLA)

HIV-1 Infection

Spain
MRC/UVRI and LSHTM Uganda Research Unit
Janssen Pharmaceuticals

Recruiting

Improving HIV-1 Control in Africa With Long Acting Antiretrovirals (IMPALA)

HIV-1-infection

South Africa, Kenya, Uganda
ViiV Healthcare
Janssen Pharmaceuticals

Completed

A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries

HIV Infections

Germany, Netherlands, France, Belgium, Spain
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

Human Immunodeficiency Virus Type 1 (HIV-1)

United States, Spain, Canada, United Kingdom, South Africa, Japan
Cerecin

Terminated

Tricaprilin Liquid Formulation PK Study

Alzheimer Disease

Australia
GlaxoSmithKline

Completed

A Healthy Volunteer And Patient Study To Assess The Safety, Tolerability And Pharmacokinetics Of GSK1265744

HIV Infection

United States
Africa Health Research Institute

Recruiting

Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT (LAPIS)

HIV Infections

South Africa
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

HIV Infections

Zimbabwe, South Africa, Botswana, Kenya, Malawi, Uganda, Swaziland

3

Subscribe